|
|
|
29.06.26 - 08:42
|
Enhertu approved in EU for HER2+ solid tumours (Cision)
|
|
|
29 June 2026
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which demonstrated clinically meaningful responses across a broad range of tumours
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC]...
|
|
|
29.06.26 - 08:06
|
Datroway recommended for approval in EU for TNBC (Cision)
|
|
|
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Recommendation based on TROPION-Breast02 Phase III trial where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
If approved, Datroway has the potential to be the first TROP2-directed antibody drug conjugate for patients in the EU with a...
|
|
|
|
|
|
|
|
|
26.05.26 - 08:01
|
Enhertu recommended in EU for HER2+ solid tumours (Cision)
|
|
|
26 May 2026
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours
If approved, Enhertu would become the first HER2-directed therapy and
antibody drug conjugate to receive a tumour agnostic indication in the EU
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a...
|
|
|
26.05.26 - 08:01
|
Datroway approved in US for 1L triple-negative BC (Cision)
|
|
|
26 May 2026
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo's Datroway is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 Phase III trial
Datroway has the potential to become the new standard of care in this setting...
|
|
|
|
|
25.05.26 - 12:00
|
AstraZeneca, Daiichi Sankyo′s Datroway receives FDA approval for TNBC (PBR)
|
|
|
The approval allows Datroway to be used as a first-line treatment for adults with unresectable or metastatic TNBC who cannot receive programmed cell death protein 1 (PD-1) or
The post AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
18.05.26 - 08:06
|
Enhertu approved in two HER2+ early BC settings (Cision)
|
|
|
18 May 2026
Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Approved for use before surgery based on DESTINY-Breast11 Phase III trial
Approved for use following surgery based on DESTINY-Breast05 Phase III trial
Two new indications bring AstraZeneca and Daiichi Sankyo's Enhertu into curative-intent setting, reinforcing its role across stages of HER2-positive breast cancer
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant...
|
|
|
|
|
|
|
12.05.26 - 07:24
|
Daiichi Sankyo Sees Strong Growth Despite One‑Off Costs (Bloomberg)
|
|
|
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below market expectations. The Japanese drugmaker reported double‑digit growth and rising revenue, supported by robust demand for its flagship cancer treatments.
The company also outlined its medium‑term outlook, highlighting antibody‑drug conjugates, research investment and the role of artificial intelligence, even as competition intensifies and currency moves remain a factor.
Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, spoke exclusively with Shery Ahn on Insight with Haslinda Amin about results, strategy and growth priorities. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
11.05.26 - 09:36
|
Daiichi Sankyo Earnings Fall; Guides FY27 (AFX)
|
|
|
TOKYO (dpa-AFX) - Daiichi Sankyo Co. Ltd. (DSKYF, 4568.T, DSNKY), a Japanese pharmaceutical company, on Monday reported lower net income in the full year ended March 31, 2026 compared with the pre......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
